KAYO MOTOR
834058
Zhejiang Zoenn Design
300901
Zhejiang Meorient Commerce & Exhibition Inc.
300795
Fujian Zitian Media Technology
300280
Zhejiang Prulde Electric Appliance
301353
CN Stock MarketDetailed Quotes
688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- 8.43
- -0.22-2.54%
Market Closed Dec 13 15:00 CST
8.74BMarket Cap83.47P/E (TTM)
8.67High8.41Low44.22KlotVolume8.65Open8.65Pre Close37.63MTurnover0.62%Turnover Ratio80.29P/E (Static)1.04BShares10.2952wk High3.72P/B5.99BFloat Cap6.0252wk Low10.38Limit Up710.57MShs Float42.07Historical High6.92Limit Down3.01%Amplitude6.02Historical Low0.09Dividend TTM8.51Avg Price28.55KlotAsk1.07%Div YieldTTM100Lot Size14.44KlotBid
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. News
Fudan Zhangjiang Announcement on Plans to Reduce Shareholdings by Shareholders Holding 5% or More
Fudan Zhangjiang: Fudan Zhangjiang Voluntary Disclosure Notice on Acceptance of Drug Marketing Applications for Obecholic Acid Tablets to Treat Primary Biliary Cholangitis
Fudan Zhangjiang Voluntary Disclosure Notice Concerning Acceptance of Drug Marketing Applications for Obecholic Acid Tablets to Treat Primary Biliary Cholangitis
Fudan Zhangjiang Third Quarter Report 2024
Announcement of Fudan Zhangjiang on holding the results briefing for the third quarter of 2024
Fudan Zhangjiang: Fudan Zhangjiang H share announcement
Fudan Zhangjiang: Fudan Zhangjiang H share announcement
Fudan Zhangjiang H-share announcement
Fudan Zhangjiang H-share announcement
Fudan Zhangjiang: Fudan Zhangjiang H share announcement
Fudan Zhangjiang H-share announcement
Fudan and Zhangjiang voluntarily disclosed an announcement on the completion of the US Phase II clinical trial of injectable hempofen to treat erythematous moles
Fudan Zhangjiang Announcement on Participating in the 2024 Semi-Annual Pharmaceutical and Biological Products Special Group Performance Briefing
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily disclosed an announcement regarding the completion of the enrollment of the first subject in the phase III clinical trial of the injection of FDA018 antibody conjugate for the treatment of triple-negative breast cancer.
Announcement from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Regarding the Resignation of Core Technical Personnel
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. 2024 Interim Equity Dividend Implementation Announcement
Announcement of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.'s special report on the use and placement of fundraising during the first half of 2024.
Announcement of the Resolution of the Sixth Meeting of the Eighth Supervisory Committee of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
Mid-year evaluation report of the 'Improving Efficiency and Returning More' action plan for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. in 2024.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Half-Year Report for 2024.
